GeneDx (WGS) vs. Its Rivals Head-To-Head Survey

GeneDx (NASDAQ:WGS) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it contrast to its peers? We will compare GeneDx to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations for GeneDx and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	1	7	0	2.67
GeneDx Competitors	1837	7675	13204	813	2.55

GeneDx presently has a consensus price target of $90.86, suggesting a potential upside of 36.59%. As a group, “Healthcare Providers & Services” companies have a potential upside of 10.61%. Given GeneDx’s stronger consensus rating and higher possible upside, research analysts clearly believe GeneDx is more favorable than its peers.

Insider & Institutional Ownership

61.7% of GeneDx shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 25.2% of GeneDx shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

GeneDx has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, GeneDx’s peers have a beta of 1.08, indicating that their average share price is 8% more volatile than the S&P 500.

Profitability

This table compares GeneDx and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	N/A	N/A	N/A
GeneDx Competitors	142.35%	-0.16%	-4.98%

Earnings & Valuation

This table compares GeneDx and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
GeneDx	$454.43 million	N/A	-18.27
GeneDx Competitors	$1.66 billion	$11.00 million	6.79

GeneDx’s peers have higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

GeneDx beats its peers on 8 of the 12 factors compared.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.